Posted in | News | Plastics and Polymers

European Union Concludes No Significant Risks Associated with TBBPA

On 15 January, the European Commission’s Scientific Committee SCHER adopted its opinion on the environmental part of the TBBPA Risk Assessment, which was concluded in June 2007. The SCHER Opinion considers that “the environmental part of the risk assessment of tetrabromobisphenol-A is in general of good quality”.

The SCHER in principle agrees with the conclusions presented in the Risk Assessment Report (RAR). The RAR identified no significant risk from the reactive use of TBBPA such as in epoxy resin for printed circuit boards. A risk for soil, sediment and water was confirmed at the plastic production stage when TBBPA is added to one specific type of plastics (ABS). As a result, the EU approved a Risk Reduction Strategy which addresses this risk through industrial site emissions reduction and therefore does not recommend restrictions on TBBPA’s marketing and use.

The SCHER Opinion recommends conclusion i) for possible TBBPA degradation to Bisphenol-A. This is already fully reflected in the RAR conclusions, which emphasized that “no risks are currently identified” for this scenario.

The Commission will reference the SCHER Opinion, together with the now closed RAR and the Risk Reduction Strategy (RRS), when publishing its final Recommendation on TBBPA in the Official Journal. The conclusion of TBBPA’s RAR will enable a smooth transition of TBBPA through the REACH registration procedure, as the science needed to register TBBPA is already completed.

To view the statement, go to the BSEF website, please or http://www.bsef.com/newsmanager/uploads/scher_statement_final_290108__2_.pdf

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.